Drug recall · March 11, 2020
Methylprednisolone Acetate/Bupivacaine Hydrochloride Injectable Suspension recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Methylprednisolone Acetate/Bupivacaine Hydrochloride Injectable Suspension, METHYLPRED ACETATE/BUPIVACAINE HCL [10ML] CMC 80MG/5MG/ML INJ SUSP, For IM, IA Use, Shake Well, 10 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0624-1
- Lots / codes
Lot #: 09042019+52876, Exp 3/2/2020
- Quantity
- N/A
- Company
- Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical, Los Angeles, CA
- Distribution
- U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic
- Initiated
- January 15, 2020 · Voluntary: Firm initiated
- Classified
- March 5, 2020
- Reported
- March 11, 2020
- Ended
- December 7, 2023
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Methylprednisolone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.